Vaccine demands to achieve outbreak control for MPXV Clade I with one-time mass campaign in sub-Saharan Africa: scenario-based modelling study

Authors: Shihui Jin[1], Toshiaki R Asakura[2,3,4], Hiroaki Murayama[5], David Niyukuri[6,7,8], Diafuka Saila-Ngita[9], Jue Tao Lim[10], Akira Endo[1,4,#], Borame L Dickens[1,#]

1. Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore

2. Department of Infectious Disease Epidemiology and Dynamics, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK

3. Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK

4. School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan

5. School of Medicine, International University of Health and Welfare, Narita, Japan

6. Doctoral School, University of Burundi, Bujumbura, Burundi
7. Department of Mathematics, University of Burundi, Bujumbura, Burundi
8. The South African Department of Science and Technology-National Research Foundation (DST-NRF) Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Cape Town, South Africa
9. Department of Infectious Disease and Global Health, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA, USA
10. Lee Kong Chian School of Medicine, Nanyang Technological University

#These authors contributed equally.

Correspondence to: ephdbsl@nus.edu.sg, National University of Singapore, 117549, Singapore

Abstract

Background

Declining cross-protection from historical smallpox vaccination campaigns and persistent zoonotic reservoirs
leave many sub-Saharan countries susceptible to mpox outbreaks. With millions of vaccine doses made
available to the region since late 2024, estimating the country specific impact of one-time mass vaccination
strategies is crucial for ongoing outbreaks and for other countries at future risk.

Methods

We adapted a next generation matrix model to incorporate vaccination which was calibrated using mpox
datasets from the Democratic Republic of Congo. We projected the effective reproduction number, R_{eff}, for 47
sub-Saharan countries from 2025 to 2050 under four transmission scenarios with different contributions of
community vs sexual contacts, informed by Clade Ia and Ib outbreaks. We then calculated country-specific
minimum vaccine coverages required for outbreak control and evaluated one-time age-specific mass vaccination
strategies for reducing R_{eff}.

Findings

For all 47 countries, R_{eff}s are projected to rise. At least 20 are estimated to require vaccination in 2025, and 36
in 2050, in the event of national outbreaks. For eleven clade I-affected countries, the minimum required
coverage is estimated to range from 0%–4.8% to 14.5%–19.5% in 2025 with increasing sexual transmission,
increasing to 0%–10.8% and 22.6%–26.0% in 2050 , respectively. The prioritised age group for vaccination
shifts from 0–4 to 20–29 with additional sexual transmission.

Interpretation

With diminishing smallpox-vaccination-induced immunity, increasing R_{eff}s and potential for persistent
outbreaks are expected for mpox. Policymakers may face increasing vaccine demand, which will necessitate
coordinated efforts to prioritise high-risk groups under supply constraints.

Keywords

Clade I MPXV; Mass vaccination; Short-term projection; Sub-Saharan Africa; Vaccine demand

1. Introduction

The monkeypox virus (MPVX), causing mpox disease, has now been responsible for multiple international outbreaks with sustained human-to-human transmission across its two clades: Clade I and Clade II. Historically, mpox has been reported in rural, forested areas within central and west Africa where infection is suspected to primarily occur through zoonotic exposure with limited human spread from close physical contact.[1] In 2023 however, the epidemiology of Clade I shifted with the emergence of the subclade Ib, an offshoot of Clade I. For this subclade, evidence exists of more sustained and rapid spread through physical and sexual contact in the general population,[2] with the greatest proportion of reported cases being among children under five and young adults aged 20–29[3] as well as high risk populations such as sex workers and their clients.[4] Overall, since January 2024, over 50,000 cases and 1000 deaths have been reported in the Democratic Republic of Congo (DRC) and surrounding affected countries for both subclades combined.[3]

With Clade I currently estimated to have higher case fatality ratios (up to 12% versus 3.6% for Clade II),[5] public health systems within sub-Saharan Africa are concerned about the potential impacts of Clade I importations and outbreaks. This is exacerbated by waning cross-protection from historical smallpox vaccination campaigns,[6] which had coverage of more than 90% across sub-Saharan Africa at its peak[7] and ended around the time when the World Health Organisation (WHO) declared smallpox to be eradicated in 1980. Overall, the persistence of mpox, increasing transmissibility between humans, and loss of cross-protection, have supported immunisation strategies using third-generation smallpox vaccines that show improved safety profiles. The effective coordination and planning for the distribution of these vaccines and stockpiling will be of priority, which should be guided by evidence and scenario-based demand assessments and projections.

Over 5.85 million vaccine doses are expected to be available to the Vaccines Access and Allocation Mechanism for mpox by the end of 2024 including 2.85 million doses of the MVA-BN smallpox vaccine and over three million doses of the LC16m8 smallpox vaccine.[8] Both vaccines have shown an effectiveness ranging from 70–90%.[9–11] As of 9 November 2024, nine countries including Central African Republic, Côte d'Ivoire, the Democratic Republic of the Congo, Kenya, Liberia, Nigeria, Rwanda, South Africa, and Uganda have been prioritised for receiving doses through the Access and Allocation Mechanism by the WHO and partners.[12] These efforts are critical but coverage will be limited as the total population size in these countries is nearly 0.6 billion as of 2024, rising to over 1.2 billion for sub-Saharan Africa where more countries could be potentially at risk.[13] With Clade I mpox outbreaks expected to continue occurring across this region due to the persistent zoonotic reservoir, the increase in transboundary movement of people and transmissibility of Clade I MPXV, the future demand of vaccines for a responsive mass vaccination campaign against mpox outbreaks needs to be estimated for stockpiling estimations and effective outbreak control.

Firstly considerations are required on how these vaccines should be distributed considering both waning smallpox immunity and the contribution of sexual and non-sexual contact to overall transmissibility. Secondly, estimates of the country-specific differences in the number of doses required to avert outbreaks, according to differences in demographics and size of high risk populations, are required to assist in short-term vaccine stockpiling. Thirdly, in the event that mass immunisation coverage is limited, determining which age groups require prioritisation can assist in minimising health impacts.

To explore these, we constructed a mathematical model of mpox vaccination program, adapted from a preliminary study,[14] to project the transmission potential of mpox in 47 sub-Saharan African countries at high risk of case importation and outbreak. This model was then utilised to estimate the minimum vaccine stockpiles required to prevent epidemic growth under four transmissibility scenarios of increasing levels in sexual transmission. We then explored the impacts of sequential and equal vaccination distribution across age groups when supplies were limited. Our findings aim to provide detailed and practical guidance for policy-makers to tailor efficient vaccination strategies, ensuring the optimal use of available resources and enhancing outbreak preparedness.

2. Methods

2.1 Overview

Our analyses focused on the impact of a one-time mpox vaccination campaign on reducing disease transmissibility in 47 sub-Saharan African countries, evaluating outcomes at five-year intervals from 2025 to 2050. We used country-specific data to model geospatial variations in transmission dynamics, including population projections by age and sex, age-dependent contact matrices, smallpox vaccination coverage, and estimates of the population sizes of the high sexual activity groups (Table S1–S2).[7,13,15,16]

Considering the large regional discrepancies in the contribution of sexual transmission to overall disease dynamics and the differences in transmission patterns between Clade Ia and Ib mpox outbreaks, as identified in our preliminary study,[14] we modelled four hypothetical Clade I outbreak scenarios with varying levels of sexual transmission, ranging between that observed in historical Clade Ia outbreaks in the endemic provinces and the ongoing 2024 – 2025 Clade Ib outbreak in South Kivu, the DRC. These levels include:

1. Community contact only: with disease transmission exclusively explained by community (home) contact;
2. Low sexual transmission: community contact with additional sexual contact contributing 9.1% (95% confidence interval [CI]: 6.1%–13%) of the overall transmissibility in the DRC in 2024;
3. Moderate sexual transmission: community contact with additional sexual contact contributing 31% (95% CI: 26%–35%) of the overall transmissibility in the DRC in 2024; and
4. High sexual transmission: community contact with additional sexual contact contributing 52% (95% CI: 48%–55%) of the overall transmissibility in the DRC in 2024.

The parameterization of these scenarios is detailed in the Supplementary Information (Table S3).

2.2 Model of Clade I MPXV transmission dynamics

To model the effect of vaccination on the Clade I MPXV transmission dynamics in sub-Saharan African countries, we employed the next generation matrix model from the previous study[14] calibrated to historical and recent Clade I MPXV outbreaks. The next generation matrix represents the heterogeneous transmission patterns between multiple population groups and its largest eigenvalue gives the effective reproduction number R_{eff}. The original model used empirical contact survey data from Zimbabwe and age-dependent susceptibility parameters to characterise transmission of Clade Ia MPXV through regular community contact between age groups. For Clade Ib, the population was further stratified by sex and sexual activity level, and frequent sexual contact among the high-sexual-activity group (a subset of individuals aged 15–49 years) was also assumed to contribute to transmission in addition to community contacts. To ensure generalisability and consistency across countries beyond the scope of the original model (i.e., the DRC and Burundi), we introduced minor adaptations to the model: we replaced the empirical contact matrix with the synthetic contact matrices (home contact only), which are available for most of the African countries; the assumed size of high-sexual activity groups in the model was rescaled for each country according to the reported population size estimates of sex workers and males engaging in commercial sex;[16,17] age-specific coverage of the historical smallpox vaccination was varied between countries using previous estimates by Taube et al.[7] The adapted model was then re-calibrated to mpox case data in the DRC. A total of 1000 sets of updated parameter estimates were generated and used in the subsequent analysis for the 47 sub-Saharan African countries included in this study. See the Supplementary Information for further details of the model and the calibration process.

2.3 Projection of the possible future effective reproduction numbers of Clade I MPXV in sub-Saharan African countries

Using the estimated smallpox vaccine effectiveness and country-specific smallpox vaccine coverage estimates by year of birth,[7] we projected the time evolution of the next generation matrix in each country from 2025 to 2050, where we adjusted the susceptibility among different age groups (reflecting the smallpox-immunised proportion) as they age, assuming age-dependent contact patterns remain similar over time. Following

145 Murayama et al.,[14] the time- and country-dependent R_{eff} was computed as the largest eigenvalue of the next
146 generation matrix, which was scaled to be consistent with an estimate of $R_{eff} = 0.82$ for Clade Ia MPXV in
147 2015 (midpoint of the study period of 2013–2017) in the DRC.[18]

2.4 Minimum and optimal vaccine coverage to prevent epidemic growth

To inform potential future vaccine rollout strategies, we determined the optimal vaccine coverage by age group
that prevents the epidemic growth of Clade I MPXV. We used an iterative approach, starting from an entirely
unvaccinated population. We allocated each incremental set of n vaccine series—where n was less than 1% of a
country's total population size—to the group which would most efficiently reduce R_{eff}. We set an upper limit
of 80%[19] on the vaccine uptake for any age group (which we varied in the sensitivity analysis). The
effectiveness of mpox vaccines was assumed to be 80% following JYNNEOS two-dose regimen (which we also
varied in the sensitivity analysis).[9] The iteration was repeated until the herd immunity threshold $R_{eff} < 1$ was
achieved. Further details are described in the Supplementary information.

We included all age groups as vaccine-eligible in the main analysis but as additional analyses we also explored
two other scenarios: (i) only individuals aged 20 years or older being eligible for vaccination; (ii) assuming
prioritised vaccination campaign for females in the high-sexual-activity group, who consist of separate groups
and may have a higher uptake under the optimal allocation.

2.5 Mass vaccination strategies with limited vaccine supply

With currently limited vaccine supply, we assumed fixed dose availability of 5%, 10%, 20%, or 30% of the
population and evaluated different prioritisation strategies across age groups. A total of 10 vaccination strategies
were proposed, targeting age groups prioritised in the optimal vaccine allocation strategies in 2.4. Within each
set of prioritised age groups, vaccines were allocated by the following approaches:

A. Sequential vaccination: Vaccines were allocated to one group at a time until the maximum uptake
threshold was reached before reallocating the remaining doses to the next priority group.

B. Equal vaccination: Vaccines were equally distributed across the selected age groups (≥ 2).

We also classified strategies based on whether they included or excluded childhood vaccination. The full list of
vaccine strategies evaluated in this study is detailed in the Supplementary Information (Table S4). The strategies
were assessed by changes in the resulting R_{eff}s.

All the analyses and visualizations were performed using the R software version 4.1.2.[20] Analytical scripts are
available at https://github.com/ShihuiJin/onetime_mpox_vaccination/tree/main.

3. Results

3.1 Projected effective reproduction number of Clade I MPXV in 47 sub-Saharan African countries

Without assuming mpox vaccination rollout, our model projected a gradual increase in R_{eff} from 2025 to 2050 across the 47 sub-Saharan African countries, with minor-to-moderate geographical disparity. In the scenario with community contact only, for example, while R_{eff}s in 27 of these countries were projected to remain lower than one in 2025, only 11 may remain so by 2050, mainly explained by the reduced smallpox-vaccine-induced population immunity as cohorts previously vaccinated against smallpox would age out of the population. The added route of sexual transmission did not qualitatively affect R_{eff} in the low-sexual-transmission scenario. In contrast, in the moderate- or high-sexual-transmission scenarios, the projected R_{eff} substantially exceeded one for all countries, mostly around 1.3 for the moderate-sexual-transmission setting and 1.8 for the high-sexual-transmission setting in 2025 (Figure 1, Figure S1).

Figure 1. Projected R_{eff} for the 47 sub-Saharan African countries at five-year intervals from 2025 to 2050. Countries within the same geospatial subregions are grouped in the same row and arranged in descending order by their estimated R_{eff} in 2050. The four columns correspond to the four hypothetical scenarios with varying levels of sexual transmission.

3.2 Minimum vaccine coverage required for preventing epidemic growth

The estimated minimum vaccine coverage required to prevent epidemic growth (i.e., $R_{eff} < 1$) increased substantially over time and with higher levels of sexual transmission. In the scenario with only community contact, 20 out of the 47 modelled countries would require vaccination in 2025, as the corresponding R_{eff} was

projected to be at least one. This number was projected to rise to 36 by 2050. However, in the high-sexual-transmission scenario, more closely representing the spread of Clade Ib in South Kivu, the DRC in 2024, all these sub-Saharan African countries would require a coverage of at least 14.5% (95% CI: 12.2%–17.4%) to prevent epidemic growth by 2025 and the number was projected to rise to 16.9% (95% CI: 12.6%–21.1%) by 2050 (Figure 2). The numbers of vaccine series required for each country in 2025 and 2050, together with estimates under alternative vaccine-eligibility scenarios, are provided in the Supplementary Information (Figure S2–S5, Table S5–S6)

Figure 2. Projected minimum vaccine demand to prevent epidemic growth. Shown are the vaccine coverage (Row 1 and 2) and the number of individuals requiring vaccination (Row 3 and 4) to prevent epidemic growth in each sub-Saharan country modelled for 2025 (Row 1 and 3) and 2050 (Row 2 and 4), assuming the vaccine target group is defined only by age. The four columns correspond to the four hypothetical scenarios with varying levels of sexual transmission. Countries which do not require vaccination are coloured in white, with borders outlined in dark grey.

Regarding the distribution of vaccines in the population under the optimal vaccine allocation strategies, age group prioritisation within countries requiring larger vaccination coverage was similar (Figure 3). With

community contact only, the age group of 0–4 years generally required the highest vaccine coverage across time and space, followed by the 5–9 years group in a few countries including Senegal, Côte d'Ivoire and Mauritania by 2025. The projections revealed that the highest possible coverage rates among children aged under 10 years would be required for Senegal in particular as they have high household contact.[21] In total, 18 countries would require at least 1% coverage. By 2050, this number of countries would increase to 36. In the high-sexual-transmission scenario, the age group requiring the highest uptake rate shifted to 20–29 years, with 30–39 years emerging as the second priority group, albeit with a lower coverage compared to 20–29 years. The third group to target was 15–19 years, though minimal coverage was required for this age group to prevent epidemic growth in most countries (Figure 3).

Figure 3. Optimal vaccine allocation strategy to prevent epidemic growth by age group across the 47 sub-Saharan African countries. Expected number of vaccine series per capita allocated to each age group are displayed in rectangles, with widths indicating the average share of individuals receiving mpox vaccine and belonging to this age group in the general population across the 1000 simulations. Coverage levels for each age group are presented by the shading within the corresponding rectangles. Countries are arranged in descending order by the projected minimum vaccine demand to reduce R_{eff} to below 1 in 2050.

3.3 Impacts of vaccination strategies assuming limited vaccine supply and sequential allocation

When determining the minimal vaccine coverage, we allowed the algorithm to explore age-group prioritisation based on the calibrated parameter values. On the basis of the findings, sequential allocation strategies across prioritised age groups were explored assuming varying coverage levels in the population (Table S4). Compared to the equal distribution approaches (see Supplementary Information for details), the sequential allocation strategies were found to be equally or more effective. Under the community-contact-only scenario, prioritising 0–4 years was projected to lead to only three of the 47 countries being susceptible to epidemic growth in 2025, even at a 5% coverage of the overall population. Meanwhile, in the high sexual transmission scenario, prioritising individuals aged 20–29 years, followed by 30–39 years for remaining doses, could lower the median R_R_{eff} across the 47 countries in 2025 to 1.28 with 10% vaccine coverage and further to 0.97 when the coverage doubled. A coverage rate of 20% was projected to suffice for preventing epidemic growth in most countries by 2025 where prioritising individuals aged 20–29 years, then 30–39 and 40–49 was estimated to lower the expected R_{eff} of 38 countries among the 47 modelled to below one across all four hypothetical scenarios, increasing to 45 countries with 30% coverage (Figure 4, Figure S6).

Figure 4. Estimated R_{eff} in 2025 under diverse vaccination strategies. For each of the 47 countries, doses were allocated using two allocation methods, including sequential (first five rows) and equal (last five rows). Four coverage rates—5%, 10%, 20%, and 30%—were assessed, with outcomes summarized as shaded distributions in purple, blue, orange, and red, respectively. The four columns correspond to the four hypothetical scenarios with varying levels of sexual transmission.

The temporal variation in impacts of two vaccination strategies on reducing transmissibility is visualised in Figure 5, in which we focused on 11 countries with documented local transmission Clade I MPXV.[22] Their effectiveness in reducing transmissibility, assuming fixed coverage, diminished over time, with the strategy prioritising children consistently outperforming the other in scenarios with community contact only or low sexual transmission. However, at 30% coverage, the adult-targeted strategy was the only one to maintain R_{eff} below one across all four hypothetical scenarios in the 11 countries from 2025 to 2050 (Figure 5, Figure S7).

Figure 5. Projected R_{eff} at five-year intervals from 2025 to 2050 under two sequential vaccination strategies for sub-Saharan African countries with documented local transmission of Clade I MPXV as of December 2024.[22] The two vaccination strategies prioritised children aged 0–4 (Row 1 and 2) and young adults aged 20–29 (Row 3 and 4), respectively. Two coverage rates, 5% (blue) and 30% (red), were assessed. Outcomes are presented as scattered rectangles for the hypothetical scenario with community contact only and as circles for the scenario with high sexual transmission. Data points corresponding to an expected R_{eff} greater than one are highlighted in darker shades.

4. Discussion

In this study, we developed a mathematical framework to quantify the future trajectory of the transmissibility of Clade I MPXV under different vaccination strategies. By integrating country-specific demographic profiles and contact patterns, we projected R_{eff} for potential Clade I outbreaks across 47 sub-Saharan African countries between 2025 and 2050, under hypothetical scenarios with varying levels of sexual transmission and assuming a one-time mass vaccination campaign targeting specific age groups prior to the outbreak. The population-wide vaccine coverage necessary to prevent epidemic growth would range 15%–20% in a typical sub-Saharan country, but would exceed 30% for countries with high community contact in 2025 under the scenario reflecting transmission dynamics of the 2024 Clade Ib outbreak in South Kivu, the DRC.

Our projections indicate the significant influence of diminishing population-level immunity from smallpox vaccination on the overall R_{eff}, with up to a 19% increase in R_{eff} in each country over the projection window from 2025 to 2050. This decline in immunity led to a substantial rise in mpox vaccine demand. Meanwhile, the growing population in many sub-Saharan African countries, standing at 1.24 billion people as of 2024 with nearly half of the individuals aged below 20 years in 2024, further intensifies vaccine needs. In the DRC, for instance, the minimum vaccine stockpile size required to prevent epidemic growth in 2050 was estimated to increase by over 150% compared to that in 2025 assuming a similar level of sexual transmission as that in the 2024 Clade Ib outbreak. This underscores the need to enhance vaccine production capacity and to train healthcare workers to ensure smooth vaccination rollouts. More importantly, it implies the potential benefit of initiating vaccination campaigns in advance with increasing capacity, as vaccines can confer protection lasting for decades, if not a lifetime.[23]

The comparison among various mass vaccination strategies supports prioritising subpopulations with high transmission risks.[24] In the absence of sexual contact in addition to the part incorporated into community contact matrix, vaccinating individuals aged 0–4 years, who were estimated to be 41% (95% CI: 12%–82%) more likely to become infected compared to older age groups given the same contact rates, proved the most efficient in reducing R_{eff}. This finding aligns with the recommendation by Savinkina et al. to focus on vaccinating children aged under five years when resources are limited.[25] However, with an increase in the contribution of sexual transmission to overall transmissibility, the advantage of prioritising the 20–29 years cohort, the age group most likely to be highly sexually active, gradually surpassed that of targeting the 0–4 years cohort. This shift in the prioritisation of age groups highlights the importance of real-time monitoring of the age and gender composition of infections, as well as furthering our understanding on the transmission pathways of mpox. Detailed surveillance information could inform the current contribution of sexual transmission to overall disease spread, facilitating the adaptation of vaccine allocation strategy to match the prevailing transmission dynamics.

Under scenarios involving additional sexual transmission, prioritising high-sexual-activity females proved more effective than assuming uniform vaccine uptake within selected age groups (Figure S4–S5). Nonetheless, it should be noted the challenges in approaching this population due to social stigma, discrimination, and criminalization.[26] Furthermore, the high mobility of individuals within this group, in terms of the duration they remain at high sexual activity levels, may undermine the impact of prioritising this group, as they might no longer be at high transmission risk by the time an outbreak occurs.[27]

Uncertainty also exists regarding the mpox vaccine effectiveness for Clade I MPXV. In this study, we extrapolated effectiveness estimates from data on Clade IIb, assuming equivalent protection against Clade I. Sensitivity analyses assuming alternative vaccine efficacies were conducted, with results consistently substantiating prioritising children under five years or young adults aged 20–29 (Figure S11–S18). We also assumed uniform effectiveness across different age groups due to the lack of age-specific data, with effectiveness set constant during the relatively short interval between vaccination and outbreak. As more age-specific effectiveness evidence becomes available, re-evaluation of these strategies will be necessary. In addition, as of December 2024, the safety and effectiveness of mpox vaccines for young children remain uncertain,[28] especially those under five years old who are more susceptible to the disease. Therefore promoting mass vaccination among paediatric populations as suggested by our results may require careful assessment and communication.

Another essential factor influencing effectiveness of vaccination strategies is the highest achievable vaccine
uptake rate. A key determinant is the vaccine confidence levels among the target groups.[29] In this study, we
assumed 80% acceptance rate from studies on COVID-19 vaccines.[19] The sensitivity analysis testing a lower
coverage cap of 70%[30] reveals a significantly higher overall vaccine demand to achieve similar intervention
outcomes as more individuals from suboptimal age groups require vaccination (Figure S8–S10). This increase
suggests the significance of enhancing disease awareness among key populations to boost vaccine confidence
and ramp up uptake rates, especially in scenarios with constrained vaccine availability.

Another limitation of this study pertains to the focus on human-to-human transmission. Zoonotic transmission
and importation were not accounted for in the model due to the complexities of quantifying interactions between
animals and humans, as well as between travellers and residents. Under the condition of $R_{eff} < 1$, cases arising
from zoonotic spillovers or introduced from foreign countries and subsequent human-to-human transmission
may still be observed, although the outbreak is expected to be self-limiting. Neither did we incorporate cross-
protection from previous infections, due to the limited number of reported cases relative to the overall
population and the unclear age distribution.[31] In addition, the model was based on the simplified assumptions of
equal contributions to secondary infections per unit in the community contact matrix and static contact patterns
across age groups over time. Variations in secondary attack rates between contacts of different age groups or in
different countries, together with potential behaviour changes, may introduce bias to the long-term projections.

Despite the limitations, the flexible modelling framework established in our study facilitates application across a
broad geographical range of 47 sub-Saharan African countries over an extended period from 2025 to 2050,
enabling comparative analysis of regional variations in outbreak scales while highlighting the consistent
effectiveness of pre-outbreak vaccination in curbing viral transmission. Our findings highlight the critical need
for differentiated mass vaccination strategies to maximize the impact of limited vaccine supplies. Prioritising
age groups with higher infection risks—specifically young children aged 0–4 years in scenarios with community
contact only and adults aged 20–29 years in settings with high sexual transmission —can substantially reduce
disease transmissibility. Nonetheless, the most effective approach should be customized to the evolving
epidemiological landscape, informed by real-time surveillance data. This alignment between vaccination efforts
and prevailing transmission patterns will facilitate better preparedness and even pre-emption of future mpox
outbreaks at minimal cost.

Ethics Approval

No ethics approval is needed for this study.

Author contributions

S.J., A.E., and B.L.D. conceived and designed the study. S.J. implemented the statistical analysis and created the figures and tables. S.J. wrote the original draft of the manuscript. T.R.A., H.M., D.N., D.S.N., J.T.L., A.E., and B.L.D. reviewed and edited the manuscript.

Data and code availability

Data and analytical codes utilized for this study are available at
https://github.com/ShihuiJin/onetime_mpox_vaccination/tree/main.

Declaration of Interests

The authors declare no conflict of interests.

Acknowledgement

S.J. and B.L.D. are supported by the Ministry of Education Reimagine Research Grant and PREPARE, Ministry of Health. H.M., T.R.A., and A.E. are supported by the Japan Science and Technology Agency (JST) (JPMJPR22R3, to A.E.) and Japan Agency for Medical Research and Development (JP223fa627004). H.M. and A.E. are supported by the Japan Society for the Promotion of Science (JSPS) (JP22K17329, to A.E.). T.R.A. is also supported by the Rotary Foundation (GG2350294), the Nagasaki University World-leading Innovative & Smart Education (WISE) Program of the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the JSPS KAKENHI Grant-in-Aid for JSPS Fellows (JP24KJ1827). A.E. is also supported by National University of Singapore Start-Up Grant. D.S.N. is supported by USAID. J.T.L. is supported by Nanyang Technological University, Singapore – Imperial Research Collaboration Fund (INCF-2023-007). The funding sources are not involved in study design, in collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication.

References

Singh P, Sridhar SB, Shareef J, *et al.* The resurgence of monkeypox: Epidemiology, clinical features, and public health implications in the post-smallpox eradication era. *New Microbes New Infect* 2024; **62**: 101487.

Cevik M, Tomori O, Mbala P, *et al.* The 2023 – 2024 multi-source mpox outbreaks of Clade I MPXV in sub-Saharan Africa: Alarm bell for Africa and the World. *Int J Infect Dis* 2024; **146**. DOI:10.1016/j.ijid.2024.107159.

WHO. Multi-country outbreak of mpox, External situation report #42. 2024; published online Nov 9. https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report--42--9-november-2024 (accessed Dec 3, 2024).

Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, *et al.* Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. *Nat Med* 2024; : 1–5.

Beiras CG, Malembi E, Escrig-Sarreta R, *et al.* Concurrent outbreaks of mpox in Africa—an update. *The Lancet* 2025; **405**: 86–96.

Parrino J, Graham BS. Smallpox vaccines: Past, present, and future. *J Allergy Clin Immunol* 2006; **118**: 1320–6.

Taube JC, Rest EC, Lloyd-Smith JO, Bansal S. The global landscape of smallpox vaccination history and implications for current and future orthopoxvirus susceptibility: a modelling study. *Lancet Infect Dis* 2023; **23**: 454–62.

WHO. Vaccine doses allocated to 9 African countries hardest hit by mpox surge. 2024; published online Nov 6. https://www.who.int/news/item/06-11-2024-vaccine-doses-allocated-to-9-african-countries-hardest-hit-by-mpox-surge (accessed Jan 13, 2025).

Pischel L, Martini BA, Yu N, *et al.* Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis. *Vaccine* 2024; **42**: 126053.

Yeganeh N, Yin S, Moir O, *et al.* Effectiveness of JYNNEOS vaccine against symptomatic mpox disease in adult men in Los Angeles County, August 29, 2022 to January 1, 2023. *Vaccine* 2024; **42**: 125987.

Grabenstein JD, Hacker A. Vaccines against mpox: MVA-BN and LC16m8. *Expert Rev Vaccines* 2024; published online Dec 31. https://www.tandfonline.com/doi/abs/10.1080/14760584.2024.2397006 (accessed Dec 5, 2024).

WHO. WHO and partners establish an access and allocation mechanism for mpox vaccines, treatments, tests. 2024; published online Sept 13. https://www.who.int/news/item/13-09-2024-who-and-partners-establish-an-access-and-allocation-mechanism-for-mpox-vaccines--treatments--tests (accessed Jan 13, 2025).

World Bank Group. Population estimates and projections | DataBank. 2024. https://databank.worldbank.org/source/population-estimates-and-projections (accessed Nov 30, 2024).

Murayama H, Asakura TR, Dickens BL, *et al.* Roles of community and sexual contacts as drivers of clade I mpox outbreaks. 2024; : 2024.10.15.24315554.

Prem K, Zandvoort K van, Klepac P, *et al.* Projecting contact matrices in 177 geographical regions: An update and comparison with empirical data for the COVID-19 era. *PLOS Comput Biol* 2021; **17**: e1009098.

UNAIDS. AIDSinfo. 2024. https://aidsinfo.unaids.org/ (accessed Oct 6, 2024).

Semá Baltazar C, Mehta N, Juga A, *et al.* Who Are the Men Who Pay for Sex in Mozambique? Results from the National HIV/AIDS Indicator Survey 2015. *Arch Sex Behav* 2021; **50**: 2057–65.

18   Charniga K, McCollum AM, Hughes CM, *et al.* Updating Reproduction Number Estimates for Mpox
in the Democratic Republic of Congo Using Surveillance Data. 2024; published online March 6.
DOI:10.4269/ajtmh.23-0215.

19   Jin S, Cook AR, Kanwagi R, Larson HJ, Lin L. Comparing role of religion in perception of the
COVID-19 vaccines in Africa and Asia Pacific. *Commun Med* 2024; **4**: 1–9.

20   R Core Team. R: A Language and Environment for Statistical Computing. 2024. https://www.R-
project.org/.

21   USAID. The DHS Program - Country Main. 2025. https://dhsprogram.com/countries/Country-
Main.cfm?ctry_id=36&c=Senegal&r=1 (accessed Jan 13, 2025).

22   GOV.UK. Clade I mpox: affected countries. GOV.UK. 2024. https://www.gov.uk/guidance/clade-i-
mpox-affected-countries (accessed Jan 3, 2025).

23   Taub DD, Ershler WB, Janowski M, *et al.* Immunity from Smallpox Vaccine Persists for Decades: A
Longitudinal Study. *Am J Med* 2008; **121**: 1058–64.

24   Berry MT, MacIntyre CR, Cromer D, Hacker A, Davenport MP, Khoury DS. Optimal deployment of
limited vaccine supplies to combat mpox. *medRxiv* 2024; : 2024.11.03.24316551.

25   Savinkina A, Kindrachuk J, Bogoch II, *et al.* Modelling vaccination approaches for mpox containment
and mitigation in the Democratic Republic of the Congo. *Lancet Glob Health* 2024; **12**: e1936–44.

26   Benoit C, Jansson SM, Smith M, Flagg J. Prostitution Stigma and Its Effect on the Working
Conditions, Personal Lives, and Health of Sex Workers. *J Sex Res* 2018; published online June 13.
https://www.tandfonline.com/doi/abs/10.1080/00224499.2017.1393652 (accessed Dec 10, 2024).

27   Wojcicki JM. Commercial Sex Work or Ukuphanda? Sex-for-Money Exchange in Soweto and
Hammanskraal Area, South Africa. *Cult Med Psychiatry* 2002; **26**: 339–70.

28   Beeson AM, Haston J, McCormick DW, *et al.* Mpox in Children and Adolescents: Epidemiology,
Clinical Features, Diagnosis, and Management. *Pediatrics* 2023; **151**: e2022060179.

29   Mtei M, Mboya IB, Mgongo M, *et al.* Confidence in COVID-19 vaccine effectiveness and safety and
its effect on vaccine uptake in Tanzania: A community-based cross-sectional study. *Hum Vaccines Immunother*
2023; **19**: 2191576.

30   Du M, Deng J, Yan W, *et al.* Mpox vaccination hesitancy, previous immunisation coverage, and
vaccination readiness in the African region: a multinational survey. *eClinicalMedicine* 2025; **80**.
DOI:10.1016/j.eclinm.2024.103047.

31   McCollum AM, Shelus V, Hill A, *et al.* Epidemiology of Human Mpox — Worldwide, 2018–2021.
Morb Mortal Wkly Rep 2023; **72**: 68–72.